Our therapy uses the patient’s own muscle precursor cells (MPCs), isolated from a small biopsy and expanded under GMP conditions, to regenerate damaged skeletal muscle tissue.
Our initial focus is the treatment of stress urinary incontinence in women.
Compared to existing treatments which either suffer from short-term efficacy or safety concerns (more potent surgical options), our treatment is low-risk, minimally invasive and aims to provide a cure to this highly prevalent disease.